Lior Zangi

Lior Zangi

Company: Icahn School of Medicine at Mount Sinai

Job title: Associate Professor of Cardiology; Genetics & Genomic Sciences


Seminar: Therapeutic Potential of Cardiomyocytes Specific Modified mRNA Translational System 2.0 (SMRTs 2.0) with Minimally Invasive Delivery to the Heart

  • Modified mRNA is an important and safe tool to control protein expression in the heart
  • Cardiomyocytes specific modified mRNA translational system can be used to induce cardiomyocytes proliferation and cardiac regeneration post myocardial infarction
  • Cardiomyocytes specific modified mRNA translationa system 2.0 can be used with minimally invasive delivery to induce cardiac protection against ischemia or cardiac toxicity injury

Day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.